Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Diffuse large cell lymphoma (DLCL) is a significant hematologic malignancy.
• The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen is a standard treatment for DLCL.
• Dose intensity (DI) is a critical factor in chemotherapy efficacy.

Purpose of the Study:

• To evaluate the impact of dose intensity (DI) on survival outcomes in DLCL patients treated with CHOP.
• To identify prognostic factors influencing survival in DLCL patients receiving CHOP chemotherapy.

Main Methods:

• Ninety-five newly diagnosed DLCL patients treated with CHOP were analyzed.
• Dose intensity (DI) was calculated for cyclophosphamide (CTX), doxorubicin (ADM), and vincristine (VCR) during initial cycles.
• Average relative DI (ARDI) and other prognostic variables were assessed using univariate and multivariate analyses (Cox proportional hazards model).

Main Results:

• Lower dose intensity (DI) for CTX, ADM, VCR, and ARDI were associated with decreased survival in univariate analysis.
• Multivariate analysis identified ARDI less than the median and age over 60 as independent predictors of poor prognosis.
• In patients achieving complete remission, low ARDI, low CTX DI, and advanced Stage III-IV disease negatively impacted survival.

Conclusions:

• Achieving a high dose intensity (DI) in the initial cycles of CHOP chemotherapy is crucial for improving survival in DLCL.
• Average relative DI (ARDI) and patient age are significant prognostic factors for DLCL survival.
• Optimizing DI delivery in CHOP chemotherapy may enhance treatment outcomes for DLCL patients.